<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816984</url>
  </required_header>
  <id_info>
    <org_study_id>12-1972</org_study_id>
    <secondary_id>NCI-2013-00586</secondary_id>
    <nct_id>NCT01816984</nct_id>
  </id_info>
  <brief_title>PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer</brief_title>
  <official_title>A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot randomized phase I/II trial studies the side effects and best dose of PI3K&#xD;
      inhibitor BKM120 when given together with cetuximab and to see how well it works in treating&#xD;
      patients with recurrent or metastatic head and neck cancer. PI3K inhibitor BKM120 may stop&#xD;
      the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal&#xD;
      antibodies, such as cetuximab, can block tumor growth in different ways. Some block the&#xD;
      ability of tumors to grow and spread. Others find tumor cells and help kill them or carry&#xD;
      tumor-killing substances to them. Giving PI3K inhibitor BKM120 together with cetuximab may&#xD;
      kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Induction of compensatory signaling/feedback loop signaling after one week of BKM120 (PI3K&#xD;
      inhibitor BKM120) (run-in) compared to patients not treated with BKM120.&#xD;
&#xD;
      II. Safety and tolerability of combined treatment with BKM120 and cetuximab.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Induction of apoptosis after one week of BKM120 (run-in) compared to patients not treated&#xD;
      with BKM.&#xD;
&#xD;
      II. Tumor shrinkage (based Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1&#xD;
      [V1.1] measurements) in patients treated with combination.&#xD;
&#xD;
      III. Response rate (based RECIST V1.1 measurements) in patients treated with combination.&#xD;
&#xD;
      IV. Overall survival. V. Progression free survival.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of PI3K inhibitor BKM120, followed by a&#xD;
      phase II study.&#xD;
&#xD;
      RUN-IN-PERIOD: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive PI3K inhibitor BKM120 orally (PO) once daily (QD) on days -7 to 0.&#xD;
      Patients complete 1 week washout before dose escalation.&#xD;
&#xD;
      ARM II: Patients receive no treatment on days -7 to 0.&#xD;
&#xD;
      All patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and cetuximab intravenously&#xD;
      (IV) over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compensatory Signaling/Feedback Loop Signaling Evaluated by Measurement of Phosphorylated (p)-EGFR</measure>
    <time_frame>1 week</time_frame>
    <description>Performed using snap frozen tissue samples using the well-established PamGene Kinase array platform available in the Salgia/Seiwert laboratories.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 days</time_frame>
    <description>Maximum tolerated dose (MTD) is defined as the dose level preceding the dose in which greater than or equal to 2 out of 3-6 patients experience a dose limiting toxicity (DLT) assessed using CTCAE v4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apoptosis Induction</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Measured by Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay on Formalin-Fixed, Paraffin-Embedded (FFPE) sections in a descriptive manner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate Assessed Using RECIST</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Percentage of patients whose cancer shrinks or disappears after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate in Patients With Prior EGFR Failure Assessed Using RECIST</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Percentage of patients with prior EGFR failure assessed using RECIST whose cancer shrinks or disappears after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Shrinkage</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Tumor shrinkage will be visualized as a waterfall plot for graphical (qualitative) comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 years and 3 months</time_frame>
    <description>Overall survival is defined as the time from study initiation to death due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>4 years and 3 months</time_frame>
    <description>Progression free survival is defined as the time from study initiation to first evidence of progression of disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma</condition>
  <condition>Recurrent Metastatic Squamous Neck Cancer With Occult Primary</condition>
  <condition>Recurrent Salivary Gland Cancer</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Verrucous Carcinoma of the Larynx</condition>
  <condition>Recurrent Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Salivary Gland Squamous Cell Carcinoma</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage IVA Salivary Gland Cancer</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IVA Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IVA Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage IVB Salivary Gland Cancer</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IVB Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IVB Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage IVC Salivary Gland Cancer</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IVC Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IVC Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Tongue Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and after dose escalation, 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PI3K inhibitor BKM120</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)</arm_group_label>
    <other_name>BKM120</other_name>
    <other_name>PI3K_Inhibitor_BKM120</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)</arm_group_label>
    <other_name>C225</other_name>
    <other_name>C225 monoclonal antibody</other_name>
    <other_name>IMC-C225</other_name>
    <other_name>MOAB C225</other_name>
    <other_name>monoclonal antibody C225</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically / cytologically confirmed diagnosis of squamous cell carcinoma of head&#xD;
             and neck origin not amenable to curative intent therapy; both human papillomavirus&#xD;
             (HPV)(+) and HPV(-) tumors are eligible; tumors (squamous histology) of unknown&#xD;
             primary that are clearly related to the head and neck area are eligible&#xD;
&#xD;
          -  Presence of measurable lesions (RECIST V1.1)&#xD;
&#xD;
          -  Mandatory tumor biopsy/biopsies in accessible tumors; for inaccessible tumors&#xD;
             availability of tissue is required: &gt;= 10 tumor containing formalin-fixed&#xD;
             paraffin-embedded (FFPE) slides/sections&#xD;
&#xD;
          -  Progressive disease after exposure to a platinating agent (e.g. cisplatin or&#xD;
             carboplatin) in a prior line of therapy, or documented intolerance to such an agent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  No more than two lines of prior cytotoxic chemotherapy in the recurrent/metastatic&#xD;
             (palliative intent) treatment setting&#xD;
&#xD;
          -  Prior use of cetuximab or another epidermal growth factor receptor (EGFR) inhibitor is&#xD;
             allowable and if used as a single agent should not be considered as a cytotoxic&#xD;
             chemotherapy&#xD;
&#xD;
          -  Patients must have at least one site of measurable disease (if applicable) (per RECIST&#xD;
             for solid tumors or the appropriate disease classification/criteria for the target&#xD;
             population)&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelets &gt;= 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin (Hb) &gt; 9 g/dL&#xD;
&#xD;
          -  Total calcium (corrected for serum albumin) within normal limits&#xD;
&#xD;
          -  Magnesium &gt;= the lower limit of normal for the institution&#xD;
&#xD;
          -  Potassium within normal limits for the institution&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 1.5 x&#xD;
             normal range (or =&lt; 3.0 x upper limit of normal [ULN] if liver metastases are present)&#xD;
&#xD;
          -  Serum bilirubin within normal range (or =&lt; 1.5 x ULN if liver metastases are present;&#xD;
             or total bilirubin =&lt; 3.0 x ULN with direct bilirubin within normal range in patients&#xD;
             with well documented Gilbert syndrome)&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN or 24-hour clearance &gt;= 50 mL/min&#xD;
&#xD;
          -  Serum amylase =&lt; ULN&#xD;
&#xD;
          -  Serum lipase =&lt; ULN&#xD;
&#xD;
          -  Fasting plasma glucose =&lt; 120 mg/dL (6.7 mmol/L)&#xD;
&#xD;
          -  Negative serum pregnancy test within 72 hours before starting study treatment in women&#xD;
             with childbearing potential&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  International normalized ratio (INR) =&lt; 2.5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received prior treatment with a P13K inhibitor&#xD;
&#xD;
          -  No available tumor material for correlative studies&#xD;
&#xD;
          -  Patients with a known hypersensitivity to BKM120 or to its excipients, or&#xD;
             hypersensitivity to cetuximab&#xD;
&#xD;
          -  More than two prior lines of cytotoxic chemotherapy in the recurrent/metastatic&#xD;
             disease setting (palliative treatment intent)(excluding single agent use of an EGFR&#xD;
             inhibitor)&#xD;
&#xD;
          -  Patients with untreated brain metastases are excluded; however, patients with treated&#xD;
             brain metastases are eligible if they are &gt; 4 weeks from therapy completion (including&#xD;
             radiation and/or surgery), are clinically stable at the time of study entry and are&#xD;
             not receiving corticosteroid therapy at the time of study entry&#xD;
&#xD;
          -  Patients with acute or chronic liver, renal disease or pancreatitis&#xD;
&#xD;
          -  Patients with the following mood disorders as judged by the Investigator or a&#xD;
             psychiatrist, or as a result of patient's mood assessment questionnaire (treating&#xD;
             physician to decide on whether to administer questionnaire):&#xD;
&#xD;
               -  Medically documented history of or active major depressive episode, bipolar&#xD;
                  disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of&#xD;
                  suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm&#xD;
                  to others)&#xD;
&#xD;
               -  &gt;= Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v4) grade 3&#xD;
                  anxiety&#xD;
&#xD;
               -  Meets the cut-off score of &gt;= 10 in the Patient Health Questionnaire 9 (PHQ-9) or&#xD;
                  a cut-off of &gt;= 15 in the Generalized Anxiety Disorder 7 (GAD-7) mood scale,&#xD;
                  respectively, or selects a positive response of &quot;1, 2, or 3&quot; to question number 9&#xD;
                  regarding potential for suicidal thoughts in the PHQ-9 (independent of the total&#xD;
                  score of the PHQ-9)&#xD;
&#xD;
          -  Patients with diarrhea &gt;= CTCAE v4 grade 2&#xD;
&#xD;
          -  Patient has active cardiac disease including any of the following:&#xD;
&#xD;
               -  History of clinically significant heart failure (previously assessed) with a left&#xD;
                  ventricular ejection fraction (LVEF) of &lt; 50% as determined by multiple grated&#xD;
                  acquisition (MUGA) scan or echocardiogram (ECHO)&#xD;
&#xD;
               -  Corrected QT (QTc) &gt; 480 msec on screening electrocardiogram (ECG) (using the&#xD;
                  Fridericia QT correction [QTcF] formula)&#xD;
&#xD;
               -  Angina pectoris that requires the use of anti-anginal medication&#xD;
&#xD;
               -  Ventricular arrhythmias except for benign premature ventricular contractions&#xD;
&#xD;
               -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled&#xD;
                  with medication&#xD;
&#xD;
               -  Conduction abnormality requiring a pacemaker&#xD;
&#xD;
               -  Valvular disease with document compromise in cardiac function&#xD;
&#xD;
               -  Symptomatic pericarditis&#xD;
&#xD;
          -  Patient has a history of cardiac dysfunction including any of the following:&#xD;
&#xD;
               -  Myocardial infraction within the last 6 months, documented by persistent elevated&#xD;
                  cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF&#xD;
                  function&#xD;
&#xD;
               -  History of documented congestive heart failure (New York Heart Association&#xD;
                  functional classification III-IV)&#xD;
&#xD;
               -  Documented cardiomyopathy&#xD;
&#xD;
          -  Patient has poorly controlled diabetes mellitus or steroid-induced diabetes mellitus&#xD;
             (hemoglobin A1C [HbA1C] &gt; 7.5%)&#xD;
&#xD;
          -  Patients with any history of hyperglycemia (elevated blood glucose level on blood&#xD;
             chemistries) should be considered for initiation of Metformin treatment (500mg, PO,&#xD;
             twice daily) prior to starting BKM120&#xD;
&#xD;
          -  Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.,&#xD;
             active or uncontrolled infection) that could cause unacceptable safety risks or&#xD;
             compromise compliance with the protocol&#xD;
&#xD;
               -  Significant symptomatic deterioration of lung function; if clinically indicated,&#xD;
                  pulmonary function tests including measures of predicted lung volumes, diffusing&#xD;
                  capacity of the lung for carbon monoxide (DLCO), oxygen (O2) saturation at rest&#xD;
                  on room air should be considered to exclude pneumonitis or pulmonary infiltrates&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea,&#xD;
             vomiting, diarrhea, malabsorption syndrome, or small bowel resection); patients with&#xD;
             unresolved diarrhea will be excluded as previously indicated&#xD;
&#xD;
          -  Patients who have been treated with any hematopoietic colony-stimulating growth&#xD;
             factors (e.g., filgrastim [G-CSF], sargramostim [GM-CSF]) =&lt; 2 weeks prior to starting&#xD;
             study drug; erythropoietin or darbepoetin therapy, if initiated at least 2 weeks prior&#xD;
             to enrollment, may be continued&#xD;
&#xD;
          -  Patients who are currently receiving treatment with medication with a known risk to&#xD;
             prolong the QT interval or inducing Torsades de Pointes and the treatment cannot&#xD;
             either be discontinued or switched to a different medication prior to starting study&#xD;
             drug&#xD;
&#xD;
          -  Patients receiving chronic treatment with steroids or another immunosuppressive agent&#xD;
             other than specified in exclusion criterion #4&#xD;
&#xD;
               -  Note: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways&#xD;
                  diseases), eye drops or local injections (e.g. intra-articular) are allowed;&#xD;
                  patients with previously treated brain metastases, who are on stable low dose&#xD;
                  corticosteroids treatment (eg. dexamethasone 2 mg/day, prednisolone 10 mg/day)&#xD;
                  for at least 14 days before start of study treatment are eligible&#xD;
&#xD;
          -  Patients who have taken herbal medications and certain fruits within 7 days prior to&#xD;
             starting study drug; herbal medications include, but are not limited to St. John's&#xD;
             wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe,&#xD;
             saw palmetto, and ginseng; fruits include the cytochrome P450, family 3, subfamily A&#xD;
             (CYP3A) inhibitors Seville oranges, grapefruit, pummelos, or exotic citrus fruits&#xD;
&#xD;
          -  Patients who are currently treated with drugs known to be moderate and strong&#xD;
             inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or&#xD;
             switched to a different medication prior to starting study drug&#xD;
&#xD;
          -  Patients who have received chemotherapy or targeted anticancer therapy =&lt; 4 weeks (6&#xD;
             weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must&#xD;
             recover to a grade 1 before starting the trial&#xD;
&#xD;
          -  Patients who have received any continuous or intermittent small molecule therapeutics&#xD;
             (excluding monoclonal antibodies) =&lt; 5 effective half lives prior to starting study&#xD;
             drug or who have not recovered from side effects of such therapy; typically a &gt;= 2&#xD;
             week interval since completion of prior therapy is recommended and 4 weeks for&#xD;
             monoclonal antibodies&#xD;
&#xD;
          -  Patients who have received wide field radiotherapy =&lt; 4 weeks or limited field&#xD;
             radiation for palliation =&lt; 2 weeks prior to starting study drug or who have not&#xD;
             recovered from side effects of such therapy&#xD;
&#xD;
          -  Patients who have undergone major surgery =&lt; 2 weeks prior to starting study drug or&#xD;
             who have not recovered from side effects of such therapy&#xD;
&#xD;
          -  Patients who are currently taking therapeutic doses of warfarin sodium or any other&#xD;
             Coumadin-derivative anticoagulant&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding or adults of reproductive potential not&#xD;
             employing an effective method of birth control; double barrier contraceptives must be&#xD;
             used through the trial by both sexes; oral, implantable, or injectable contraceptives&#xD;
             may be affected by cytochrome P450 interactions, and are therefore not considered&#xD;
             effective for this study; women of child-bearing potential, defined as sexually mature&#xD;
             women who have not undergone a hysterectomy or who have not been naturally&#xD;
             postmenopausal for at least 12 consecutive months (i.e., who has had menses any time&#xD;
             in the preceding 12 consecutive months), must have a negative serum pregnancy test =&lt;&#xD;
             72 hours prior to initiating treatment&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) infection unless patient is&#xD;
             fully immunocompetent (cluster of differentiation 4 [CD4] &gt; 200) and patient is not&#xD;
             taking antiretroviral therapy&#xD;
&#xD;
          -  History of another malignancy within 3 years, except cured basal cell carcinoma of the&#xD;
             skin or excised carcinoma in situ of the cervix, or any tumor that is after clearing&#xD;
             with the principal investigator (PI) clearly not considered to have impact on&#xD;
             prognosis&#xD;
&#xD;
          -  Patient is unable or unwilling to abide by the study protocol or cooperate fully with&#xD;
             the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanguy Seiwert</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <results_first_submitted>September 16, 2020</results_first_submitted>
  <results_first_submitted_qc>October 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2020</results_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Verrucous</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Paranasal Sinus Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
    <mesh_term>Tongue Neoplasms</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 16, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT01816984/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
          <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>declining health status</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
          <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="47" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Compensatory Signaling/Feedback Loop Signaling Evaluated by Measurement of Phosphorylated (p)-EGFR</title>
        <description>Performed using snap frozen tissue samples using the well-established PamGene Kinase array platform available in the Salgia/Seiwert laboratories.</description>
        <time_frame>1 week</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
            <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Compensatory Signaling/Feedback Loop Signaling Evaluated by Measurement of Phosphorylated (p)-EGFR</title>
          <description>Performed using snap frozen tissue samples using the well-established PamGene Kinase array platform available in the Salgia/Seiwert laboratories.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>Maximum tolerated dose (MTD) is defined as the dose level preceding the dose in which greater than or equal to 2 out of 3-6 patients experience a dose limiting toxicity (DLT) assessed using CTCAE v4</description>
        <time_frame>28 days</time_frame>
        <population>0 patients out of 3 from the BKM 80mg/day cohort had DLT (dose limiting toxicities). 0 patients out of 9 from the BKM 100mg/day cohort had DLT.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
            <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>Maximum tolerated dose (MTD) is defined as the dose level preceding the dose in which greater than or equal to 2 out of 3-6 patients experience a dose limiting toxicity (DLT) assessed using CTCAE v4</description>
          <population>0 patients out of 3 from the BKM 80mg/day cohort had DLT (dose limiting toxicities). 0 patients out of 9 from the BKM 100mg/day cohort had DLT.</population>
          <units>mg / day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apoptosis Induction</title>
        <description>Measured by Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay on Formalin-Fixed, Paraffin-Embedded (FFPE) sections in a descriptive manner.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
            <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Apoptosis Induction</title>
          <description>Measured by Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay on Formalin-Fixed, Paraffin-Embedded (FFPE) sections in a descriptive manner.</description>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate Assessed Using RECIST</title>
        <description>Percentage of patients whose cancer shrinks or disappears after treatment.</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
            <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate Assessed Using RECIST</title>
          <description>Percentage of patients whose cancer shrinks or disappears after treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate in Patients With Prior EGFR Failure Assessed Using RECIST</title>
        <description>Percentage of patients with prior EGFR failure assessed using RECIST whose cancer shrinks or disappears after treatment.</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
            <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate in Patients With Prior EGFR Failure Assessed Using RECIST</title>
          <description>Percentage of patients with prior EGFR failure assessed using RECIST whose cancer shrinks or disappears after treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Shrinkage</title>
        <description>Tumor shrinkage will be visualized as a waterfall plot for graphical (qualitative) comparison.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
            <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Shrinkage</title>
          <description>Tumor shrinkage will be visualized as a waterfall plot for graphical (qualitative) comparison.</description>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as the time from study initiation to death due to any reason.</description>
        <time_frame>4 years and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
            <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as the time from study initiation to death due to any reason.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="5.5" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Progression free survival is defined as the time from study initiation to first evidence of progression of disease.</description>
        <time_frame>4 years and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
            <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression free survival is defined as the time from study initiation to first evidence of progression of disease.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.7" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (BKM120 PO and Cetuximab 500 mg IV 14 Days)</title>
          <description>Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. After dose escalation phase, 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.&#xD;
All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
PI3K inhibitor BKM120: Given PO&#xD;
cetuximab: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte abnormality and anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Total bilirubin increase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mood changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Leg tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>ALT Increase</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>AST increase</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Increased BUN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Everett Vokes, MD</name_or_title>
      <organization>University of Chicago Medicine and Biological Sciences</organization>
      <phone>855-702-8222</phone>
      <email>evokes@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

